quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:08·136d
SECFiling
Oculis Holding AG logo

SEC Form EFFECT filed by Oculis Holding AG

OCS· Oculis Holding AG
Health Care
Original source

Companies

  • OCS
    Oculis Holding AG
    Health Care

Recent analyst ratings

  • Dec 19UpdateAnalyst$38.00
  • Aug 27UpdateNeedham$36.00
  • Dec 5UpdateChardan Capital Markets$30.00
  • Oct 5UpdateStifel$35.00
  • Jun 14UpdateBofA Securities$22.00
  • Jun 12UpdateH.C. Wainwright$28.00

Related

  • SEC2d
    SEC Form 6-K filed by Oculis Holding AG
  • PR2d
    Oculis Publishes Invitation to the Annual General Meeting
  • PR4d
    Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
  • PR17d
    Oculis to Participate in Upcoming Investor Conferences
  • PR24d
    Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG
  • PR38d
    Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
  • PR49d
    Oculis to Participate in Upcoming Investor Conferences
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022